A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Saved in:
| Title: | A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. |
|---|---|
| Authors: | Lynce, Filipa1,2 (AUTHOR), Wang, Hongkun3 (AUTHOR), Petricoin, Emanuel F.4 (AUTHOR), Pohlmann, Paula R.1,2 (AUTHOR), Smaglo, Brandon5 (AUTHOR), Hwang, Jimmy6 (AUTHOR), He, Aiwu R.1,2 (AUTHOR), Subramaniam, Deepa S.1,2,7 (AUTHOR), Deeken, John8 (AUTHOR), Marshall, John1,2 (AUTHOR), Pishvaian, Michael J.1,2 (AUTHOR) pishvaim@georgetown.edu |
| Source: | Cancer Chemotherapy & Pharmacology. Nov2019, Vol. 84 Issue 5, p1145-1151. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
